Back to top
more

Heron Therapeutics (HRTX)

(Delayed Data from NSDQ)

$3.24 USD

3.24
1,562,240

-0.07 (-2.11%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $3.23 -0.01 (-0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

by Zacks Equity Research

Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

by Zacks Equity Research

Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.

Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CareCloud, Inc. (CCLD) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

by Zacks Equity Research

Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Recovering Industry

by Kinjel Shah

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

by Zacks Equity Research

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.

What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Heron Therapeutics (HRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

by Zacks Equity Research

Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

by Zacks Equity Research

Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 75% and 6.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -0.65% and 74.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

by Zacks Equity Research

United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -13.24% and 100.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Rebounding Industry

by Kinjel Shah

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of -4.56% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy

by Zacks Equity Research

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

by Zacks Equity Research

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.